Yu Hu

33.9k total citations · 3 hit papers
496 papers, 17.4k citations indexed

About

Yu Hu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Yu Hu has authored 496 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Hematology, 160 papers in Molecular Biology and 119 papers in Oncology. Recurrent topics in Yu Hu's work include CAR-T cell therapy research (48 papers), Multiple Myeloma Research and Treatments (43 papers) and Blood Coagulation and Thrombosis Mechanisms (40 papers). Yu Hu is often cited by papers focused on CAR-T cell therapy research (48 papers), Multiple Myeloma Research and Treatments (43 papers) and Blood Coagulation and Thrombosis Mechanisms (40 papers). Yu Hu collaborates with scholars based in China, United States and Germany. Yu Hu's co-authors include Quanwei He, Bo Hu, Huijuan Jin, Ling Mao, Yanan Li, Mengdie Wang, David Wang, Xiaoping Miao, Jiang Chang and Shengcai Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Journal of Biological Chemistry.

In The Last Decade

Yu Hu

463 papers receiving 17.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

2020 4.7k citations Yu Hu et al. profile →
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome

2020 423 citations Yu Hu et al. profile →
Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31)

2016 410 citations Heng Mei, Yu Hu et al. profile →

Peers

Countries citing papers authored by Yu Hu

Since Specialization

Citations

This map shows the geographic impact of Yu Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Hu more than expected).

Fields of papers citing papers by Yu Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Hu. The network helps show where Yu Hu may publish in the future.

Co-authorship network of co-authors of Yu Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Hu. A scholar is included among the top collaborators of Yu Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Hu. Yu Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway 2025 ·JCI Insight ·(unknown), Prajish Iyer, Meiling Jin, Elisa ten Hacken, Zachary Cartun, Kevyn L. Hart, (unknown), Kristen E. Stevenson, Laura Z. Rassenti, Emanuela M. Ghia, Thomas J. Kipps, Donna Neuberg, Ruben D. Carrasco, Wing C. Chan, Joo Y. Song, Yu Hu, Catherine A. Wu, (unknown)	0
2	Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis 2025 ·EClinicalMedicine ·Shuang Li, Guofu Zhang, Xiating Li, Shangzhi Xu, Huafang Wang, Jun Deng, Zhipeng Cheng, Fengjuan Fan, (unknown), (unknown), Liang Tang, Yu Hu	1
3	Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential 2025 ·Pharmaceuticals ·Chi Ma, Aoshuang Xu, Liping Zuo, Qun Li, Fengjuan Fan, Yu Hu, Chunyan Sun	0
4	Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients 2025 ·British Journal of Cancer ·(unknown), Jun Deng, (unknown), (unknown), Anqi Zhu, (unknown), (unknown), Qiuying Huang, Yu Hu, Qingge Li	0
5	Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects 2024 ·Pharmaceuticals ·Zhaozhao Chen, Yu Hu, Heng Mei	0
6	Tofacitinib for elderly onset hemophagocytic lymphohistiocytosis with gene mutations: a case report 2024 ·SHILAP Revista de lepidopterología ·Tingting Liu, Zhipeng Cheng, Yu Hu, Liang Tang	1
7	Natural Variation in the Promoter of GmSPL9d Affects Branch Number in Soybean 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Jiajia Li, Mingyue Wan, (unknown), Wenhui Wang, (unknown), Yu Hu, Lijuan Qiu, Xiaobo Wang	2
8	Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients 2023 ·Thoracic Cancer ·(unknown), (unknown), Miao He, Yajing Zhao, Yujia Liu, Mo Li, Guosheng Li, Xiuwen Wang, Li Li, Yu Hu	4
9	Age at SARS-CoV-2 infection and psychological and physical recovery among Chinese health care workers with severe COVID-19 at 28 months after discharge: A cohort study 2023 ·Frontiers in Public Health ·Qian Li, Lijuan Xiong, (unknown), (unknown), Yanzhao Zhang, Yunzhou Fan, Liang Tang, Yang Jin, Jiahong Xia, Yu Hu	2
10	[Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia]. 2023 ·PubMed ·Mengyi Du, (unknown), (unknown), Wanzhuo Xie, (unknown), Heng Mei, Yu Hu	3
11	Role of NLRP3 inflammasome activation in HCC cell progression 2023 ·Heliyon ·Bingling Dai, Hanbing Cao, Yu Hu, (unknown), (unknown), Yanbin Chen, Feng Liu, (unknown), Yanmin Zhang, Xinjun Lei	4
12	ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis 2023 ·Carcinogenesis ·Jiasi Zhang, Yuxi Liu, Qun Li, Liping Zuo, Bo Zhang, Fei Zhao, Fengjuan Fan, Shanshan Luo, Yu Hu, Chunyan Sun	22
13	Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies 2023 ·Blood Cancer Journal ·Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Jin Kang, Jia Xu, (unknown), Xindi Wang, (unknown), Yanlei Zhang, Di Wu, Alex H. Chang, Yu Hu, Heng Mei	52
14	LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment 2023 ·Acta Pharmaceutica Sinica B ·Huiwen Liu, Honglan Wang, Qiyu Li, Yiwei Wang, (unknown), Xuejing Li, Chunyan Sun, Önder Ergönül, Füsun Can, Zhiqing Pang, Bo Zhang, Yu Hu	16
15	Gene editing of human iPSCs rescues thrombophilia in hereditary antithrombin deficiency in mice 2022 ·Science Translational Medicine ·Liang Tang, (unknown), (unknown), (unknown), Wenyi Lin, Yuyang Zhang, (unknown), Tingting Wu, (unknown), Hui Lü, Jun Wei, Javier Corral, Yu Hu	10
16	Mechanism of Magnetic Flux Leakage Detection Method Based on the Slotted Ferromagnetic Lift-Off Layer 2022 ·Sensors ·Jian Tang, (unknown), (unknown), Yu Hu, Yihua Kang	12
17	Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China 2021 ·Cancer Communications ·(unknown), Li Wang, Jianda Hu, Wenbin Qian, Xi Zhang, Yu Hu, Qi Zhu, Bobin Chen, Depei Wu, Chung‐Chou H. Chang, Pengpeng Xu, (unknown), Juying Wei, Yao Liu, Guohui Cui, Yong Tang, (unknown), Haiwen Huang, Hongmei Yi, Weili Zhao	17
18	Possible posttraumatic stress disorder in Chinese frontline healthcare workers who survived COVID-19 6 months after the COVID-19 outbreak: prevalence, correlates, and symptoms 2021 ·Translational Psychiatry ·Lijuan Xiong, Bao‐Liang Zhong, (unknown), (unknown), Ming Huang, Jing Ding, (unknown), Jun Tong, (unknown), Jiahong Xia, Yu Hu	22
19	Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia 2020 ·Clinical Cancer Research ·Lu Tang, Jianghua Wu, (unknown), Huiwen Jiang, Min Xu, Mengyi Du, Zhinan Yin, Heng Mei, Yu Hu	88
20	Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience 2020 ·Leukemia & lymphoma ·Xiaoyan Zhao, Xuan Lu, Liang Tang, Han Yan, Wenlan Chen, Wei Shi, Zhaodong Zhong, Yong You, Linghui Xia, Yu Hu, Huafang Wang	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact